To Homepage

News

June 2023

press-releaseMR-proADM

DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ test

DiaSorin, a global leader in the In Vitro Diagnostic (IVD) field, with expertise in developing, producing, and marketing reagent kits for diagnostic laboratories for more than 50 years has launched and commercialized the LIAISON® B·R·A·H·M·S MR-proADM™ chemiluminescent immunoassay in all countries accepting CE mark.
The launch follows a Supply and Licensing Agreement signed with Thermo Fisher Scientific, the world leader in serving science, in 2022.
MR-proAD is an endothelial marker, useful in the Emergency and Intensive Care departments to assess progression as well as severity of a disease.
For more information please see here >

May 2022

press-releaseMR-proADM

DiaSorin and Thermo Fisher Scientific enter into a partnership on B·R·A·H·M·S MR-proADM for precise assessment of disease severity in critical care

DiaSorin and Thermo Fisher Scientific, the world leader in serving science, entered in a new and long-term agreement on Thermo Fisher’s biomarker testing mid-regional adrenomedullin (B·R·A·H·M·S MR-proADM). The agreement expands an already long-standing relationship between the companies for the biomarker testing using Thermo Fisher’s procalcitonin (B·R·A·H·M·S PCT). DiaSorin will develop and commercialize the new chemiluminescent immunoassay, LIAISON® B·R·A·H·M·S MR-proADM™, for the quantification of MR-proADM in human plasma samples. The new test will be part of DiaSorin’s assay portfolio for the automated LIAISON® CLIA analyzer family and will subsequently increase the availability of this biomarker for the diagnosis and critical care of patients with a first launch in Europe. MR-proADM is an endothelial marker that accurately indicates disease severity and progression due to organ dysfunction in patients suffering from, for example, infectious disease or sepsis. Recent publications (Gonzales Del Castillo et al., Eur J Intern Med 2021; 88:104-113; Saeed et al., Crit Care 2019; 23 (1):40) show that MR-proADM also identifies medically stable patients, which allows to de-escalate therapy or patient transfer to a lower level of care. The clinical utility of MR-proADM leads to an economic benefit by an improved allocation of hospital resources.
For more information please see here >

February 2022

press-releaseFinancial Reports

Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2021 Results

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2021...
Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2021 Results >

News Archive

Not all products are CE marked or have 510(k) clearance for sale in the U.S. Availability of products in each country depends on local regulatory marketing authorization status.